Prospective Multicenter Post-market Study of the Zimmer Gender Solutions Natural Knee Flex System
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Zimmer Biomet
- Primary Endpoint
- Survivorship
Study Overview
Brief Summary
This is a prospective multicenter study of the Gender Solutions Natural Knee Flex System when used in primary total knee arthroplasty. The purpose of the study is to obtain short-, Mid-, and long-term clinical outcomes and implant survivorship data for the Gender Solutions Natural Knee Flex System.
Detailed Description
Survival and outcome data on the Gender Solutions Natural Knee Flex System will be done by an analysis of standard scoring system, radiographs and adverse event records. Survivorship will be evaluated by monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated adverse device effects. Outcomes will be measured by comparing the overall pain and function performances (based on the Knee Society Scoring System), survivorship, subject quality of life and radiographic parameters of study subjects receiving the Gender Solutions Natural Knee Flex System.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient 18-75 years of age, inclusive;
- •Patient qualifies for a total knee arthroplasty based on physical exam and medical history including at least one of the following: osteoarthritis, inflammatory arthritis, post-traumatic arthritis, rheumatoid arthritis, or valgus, varus, or flexion deformities;
- •Patient has undergone a study related informed consent process;
- •Patient is willing and able to provide written consent;
- •Patient is willing and able to cooperate in the required post-operative therapy;
- •Patient is willing and able to complete scheduled follow-up evaluations.
Exclusion Criteria
- •Patient has previous history of infection in the affected joint and/or a local or systemic infection that could affect the prosthetic joint;
- •Insufficient bone stock on femoral or tibial surfaces;
- •Skeletal immaturity
- •Neuropathic arthropathy
- •Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb;
- •Stable, painless arthrodesis in a satisfactory functional position;
- •Severe instability secondary to the absence of collateral ligament integrity;
- •Patient has rheumatoid arthritis and an ulcer of the skin or a history of recurrent breakdown of the skin because of their risk of postoperative infection is greater;
- •Patient has known sensitivity or allergy to one or more of the implanted materials;
- •Patients pregnant or considered a member of a protected population (e.g., prisoner, mental incompetence, unable to understand what clinical trial participation entails, etc.)
Outcomes
Primary Outcomes
Survivorship
Time Frame: 10 years
Based on frequency of adverse events, serious adverse events, adverse device effects, serious adverse devices effects and unanticipated adverse device effects or removal of the device summarized using a Kaplan-Meier method and presented with rates (as percentages) and confidence intervals.
Secondary Outcomes
- Function Performance(10 Years)
- Pain Performance(10 years)